• Explore /
  • Poster
  • / HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.

HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.

Abstract Poster

Authors

null

Atsushi Ishiguro

Teine Keijinkai Hospital, Sapporo, Japan

Atsushi Ishiguro , Yasuyuki Kawamoto , Satoshi Yuki , Yoshimitsu Kobayashi , Kazuaki Harada , Susumu Sogabe , Yasushi Tsuji , Shintaro Nakano , Kentaro Sawada , Tetsuhito Muranaka , Hiroshi Nakatsumi , Masayoshi Dazai , Takahide Sasaki , Kazunori Eto , Michio Nakamura , Osamu Muto , Yuh Sakata , Naoya Sakamoto , Yoshito Komatsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000030372

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr TPS183)

DOI

10.1200/JCO.2019.37.4_suppl.TPS183

Abstract #

TPS183

Poster Bd #

N15

Abstract Disclosures

Similar Posters

First Author: Yasuyuki Kawamoto

First Author: Sylvie Lorenzen

First Author: Ting Han

First Author: Rika Saito